This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
NCCN Guidelines Version 7.2017. June 22, 2017. National Comprehensive Cancer Network, Inc; 2017. Available from: www.nccn.orgNCCN GuidelinesVersion 7.2017. June 22, 2017. National Comprehensive Cancer Network, Inc; 2017. Available from: www.nccn.orgSearch in Google Scholar
Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology. 2014;25: 1681–1690.KerrKMBubendorfLEdelmanMJMarchettiAMokTNovelloSSecond ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancerAnnals of Oncology2014251681169010.1093/annonc/mdu14524718890Search in Google Scholar
Zhang X, Ran Y. Prognostic role of elevated platelet count in patients with lung cancer: a systematic review and meta-analysis. International Journal of Clinical and Experimental Medicine. 2015;8(4): 5379–5387.ZhangXRanYPrognostic role of elevated platelet count in patients with lung cancer: a systematic review and meta-analysisInternational Journal of Clinical and Experimental Medicine20158453795387Search in Google Scholar
Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A. Are neutro-phil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pacific Journal of Cancer Prevention. 2013;14(9): 5237–5242.UnalDErogluCKurtulNOguzATasdemirAAre neutro-phil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?Asian Pacific Journal of Cancer Prevention20131495237524210.7314/APJCP.2013.14.9.523724175807Search in Google Scholar
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917): 860–867.CoussensLMWerbZInflammation and cancerNature2002420691786086710.1038/nature01322280303512490959Search in Google Scholar
Hattar K, Franz K, Ludwig M, Sibelius U, Wilhelm J, Lohmeyer J, et al. Interactions between neutrophils and non-small cell lung cancer cells: enhancement of tumor proliferation and inflammatory mediator synthesis. Cancer Immunology, Immunotherapy, 2014;63(12): 1297–1306.HattarKFranzKLudwigMSibeliusUWilhelmJLohmeyerJInteractions between neutrophils and non-small cell lung cancer cells: enhancement of tumor proliferation and inflammatory mediator synthesisCancer Immunology, Immunotherapy201463121297130610.1007/s00262-014-1606-z425508525186613Search in Google Scholar
Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nature Medicine. 2010;16(2): 219–223.HoughtonAMRzymkiewiczDMJiHGregoryADEgeaEEMetzHENeutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growthNature Medicine201016221922310.1038/nm.2084282180120081861Search in Google Scholar
Brambilla E, Le Teuff G, Marguet S, Lantuejoul S, Dunant A, Graziano S, et al. Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer. Journal of Clinical Oncology, 2016;34(11): 1223–1230.BrambillaELe TeuffGMarguetSLantuejoulSDunantAGrazianoSPrognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancerJournal of Clinical Oncology201634111223123010.1200/JCO.2015.63.0970487232326834066Search in Google Scholar
Oja AE, Piet B, van der Zwan D, Blaauwgeers H, Mensink M, de Kivit S, et al. Functional heterogeneity of CD4+ tumor-infiltrating lymphocytes with a resident memory phenotype in NSCLC. Frontiers in Immunology. 2018;9: 2654.OjaAEPietBvan der ZwanDBlaauwgeersHMensinkMde KivitSFunctional heterogeneity of CD4+ tumor-infiltrating lymphocytes with a resident memory phenotype in NSCLCFrontiers in Immunology20189265410.3389/fimmu.2018.02654625082130505306Search in Google Scholar
Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 107(12): 2866–2872.PetersenRPCampaMJSperlazzaJConlonDJoshiMBHarpoleDHJrTumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patientsCancer107122866287210.1002/cncr.2228217099880Search in Google Scholar
Yu Y, Qian L, Cui J. Value of neutrophil to lymphocyte ratio for predicting lung cancer prognosis: a meta analysis of 7,219 patients. Molecular and Clinical Oncology. 2017;7(3): 498–506.YuYQianLCuiJValue of neutrophil to lymphocyte ratio for predicting lung cancer prognosis: a meta analysis of 7,219 patientsMolecular and Clinical Oncology20177349850610.3892/mco.2017.1342554776628811903Search in Google Scholar
Hua Z, Liuwei G, Bin Z, Lianmin Z, Changli W. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: a systematic review and meta-analysis. Scientific Report,. 2016;6: 22618.HuaZLiuweiGBinZLianminZChangliWPrognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: a systematic review and meta-analysisScientific Report201662261810.1038/srep22618477805426939789Search in Google Scholar
Zhao Q, Yuvan Z, Zhang H, Zhang X-P, Wang H-E, Wang Z-K, et al. Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: A meta-analysis including 3,720 patients. International Journal of Cancer. 2016;139(1): 164–170.ZhaoQYuvanZZhangHZhangX-PWangH-EWangZ-KPrognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: A meta-analysis including 3,720 patientsInternational Journal of Cancer2016139116417010.1002/ijc.3006026915723Search in Google Scholar
Scilla K, Bentzen SM, Lam VK, Mohindra P, Nichols EM, Vythuis MA, et al. Neutrophil-lymphocyte ratio is a prognostic marker in patients with locally advanced (stage IIIA and IIIB) non-small cell lung cancer treated with combined modality therapy. The Oncologist. 2017;22(6): 737–742.ScillaKBentzenSMLamVKMohindraPNicholsEMVythuisMANeutrophil-lymphocyte ratio is a prognostic marker in patients with locally advanced (stage IIIA and IIIB) non-small cell lung cancer treated with combined modality therapyThe Oncologist201722673774210.1634/theoncologist.2016-0443546958728533476Search in Google Scholar
Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, et al. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS ONE. 2018;13(2): e0193018.KiriuTYamamotoMNaganoTHazamaDSekiyaRKatsuradaMThe time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancerPLoS ONE2018132e019301810.1371/journal.pone.0193018581400229447258Search in Google Scholar
Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophillymphocyte ratio: experience in patients with cancer. Critical Reviews in Oncology/Hematology. 2013;88(1): 218–230.GuthrieGJCharlesKARoxburghCSHorganPGMcMillanDCClarkeSJThe systemic inflammation-based neutrophillymphocyte ratio: experience in patients with cancerCritical Reviews in Oncology/Hematology201388121823010.1016/j.critrevonc.2013.03.01023602134Search in Google Scholar
